Skip to main content
Infant Bacterial Therapeutics logo

Infant Bacterial Therapeutics — Investor Relations & Filings

Ticker · IBT ISIN · SE0008015259 LEI · 2138008KVBXCRJGP6Z26 ST Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2026-05-07 AGM Information
Country SE Sweden
Listing ST IBT

About Infant Bacterial Therapeutics

https://ibtherapeutics.com/

Infant Bacterial Therapeutics (IBT) is a pharmaceutical company that develops drugs influencing the human infant microbiome to prevent or treat rare diseases. The company's primary focus is on premature infants, addressing urgent medical needs such as necrotizing enterocolitis (NEC), a potentially lethal inflammatory bowel disorder. Its lead drug candidate, IBP-9414, is a New Biological Entity (NBE) currently in a Phase 3 clinical study. IBT also aims to develop treatments for diseases caused by antibiotic-resistant bacteria. The company is developing its medicines for approval by regulatory agencies, including the FDA and EMA.

Recent filings

Filing Released Lang Actions
Annual General Meeting of Infant Bacterial Therapeutics
AGM Information Classification · 95% confidence The document is a press release dated May 7, 2026, detailing resolutions made at the Annual General Meeting (AGM) of Infant Bacterial Therapeutics. It lists decisions such as adoption of financial statements, board member elections, remuneration approvals, and authorization for share issuance. The content is typical of AGM information, summarizing meeting outcomes rather than providing full financial reports or detailed presentations. The document length is 2828 characters, which is relatively short and consistent with an AGM information release rather than a full Annual Report or detailed financial filing. There is no indication that this is a report publication announcement or a regulatory filing. Therefore, the document fits best under the category AGM Information (AGM-R).
2026-05-07 English
Årsstämma i Infant Bacterial Therapeutics
AGM Information Classification · 95% confidence The document is a press release dated May 7, 2026, regarding the Annual General Meeting (Årsstämma) of Infant Bacterial Therapeutics AB. It details decisions made at the AGM, including approval of financial statements, election and re-election of board members, approval of remuneration reports, authorization for share issuance, and introduction of a stock option program. The content is focused on the meeting outcomes and resolutions rather than the full annual report or financial statements themselves. The document length is 2580 characters, which is relatively short and consistent with an announcement or summary of AGM decisions rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2026-05-07 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport 1 januari – 31 mars 2026' which translates to 'Interim Report January 1 – March 31, 2026'. It contains detailed financial data for the first quarter of 2026, including net sales, operating results, earnings per share, cash flow, equity per share, and solidity. It also includes management commentary, operational updates, risk factors, and shareholder information. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content includes actual financial statements and substantive financial analysis for a period shorter than a full fiscal year (quarterly). Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-06 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January 1 – March 31, 2026' and contains detailed financial data for the first quarter of 2026, including net sales, operating income, earnings per share, cash flow, equity, and other financial metrics. It also includes a CEO message, discussion of regulatory interactions, scientific updates, risk factors, financial position, and shareholder information. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (quarterly) confirms this is a substantive financial report. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-06 English
Correction: Notice of Annual General Meeting of Infant Bacterial Therapeutics
Proxy Solicitation & Information Statement Classification · 92% confidence The document is a formal notice of the Annual General Meeting including instructions on participation, proxy details, agenda items, and board proposals sent to shareholders to obtain votes. This aligns with the Proxy Solicitation & Information Statement category rather than an actual presentation or results report.
2026-04-02 English
Rättelse: Kallelse till årsstämma i Infant Bacterial Therapeutics
Proxy Solicitation & Information Statement Classification · 88% confidence The document is a correction (“Rättelse”) of the notice (“kallelse”) to the 2026 Annual General Meeting, including full meeting agenda, proposals, voting participation instructions, proxy information, and supporting materials. It is not a post‐meeting result, nor a standalone annual or interim report, but rather materials sent to shareholders to provide information and solicit votes. This maps directly to a Proxy Solicitation & Information Statement (PSI).
2026-04-02 Swedish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.